



VIA HAND DELIVERY OCTOBER 2, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Shi et al.

Attorney Docket No.: PT005P4C1

Application Serial No.: 10/067,761

Filed: February 8, 2002

Examiner: Unassigned

Art Unit: 1644

Title: Serine Protease Polynucleotides, Polypeptides, and Antibodies

1644
#6
11/7/02
RECEIVED

OCT 15 2002

TECH CENTER 1600/2900

RESPONSE TO REQUIREMENT FOR STATEMENT UNDER 42 U.S.C. § 2182

ATTN: LICENSING AND REVIEW SECTION

Commissioner for Patents

Washington, D.C. 20231

RECEIVED

OCT 31 2002

Sir:

GROUP 3600


In response to the Requirement mailed on September 6, 2002, Applicants respectfully assert that the above-captioned application is not "useful in the production or utilization of special nuclear material or atomic energy" within the scope of 42 U.S.C. § 2182, and thus no statement should be required.

However, assuming *arguendo* that the Requirement is proper, Applicants submit herewith the statement required by 42 U.S.C. § 2182, executed by all of the inventors of the above-captioned application. Accordingly, the Requirement and 42 U.S.C. § 2182 have been fully complied with.

No fee is believed due in connection with this submission. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 08-3425.

Respectfully submitted,

Dated: October 2, 2002


Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosure